Relapsing multiple sclerosis (RMS) is an autoimmune disorder in which the body attacks itself. Specifically, the immune system attacks the coating (the myelin sheath) on the nerves in the brain, spinal cord, and eye area, which can cause scarring and prevent the nerves from communicating correctly. This communication breakdown can lead to symptoms of MS, which can vary in severity, and may lead to permanent damage.
Rebif® is a form of interferon beta, an immunomodulator which helps to regulate the immune system. Rebif® is similar to the type of interferon beta produced naturally in your body. When you have RMS, treatment with an interferon therapy may reduce the activity of cells that are attacking your nervous system.
The precise way in which Rebif® works in MS is not known. Talk to your healthcare provider to find out what Rebif® may mean for you and your RMS.
IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information
Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.
Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.
Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of Rebif include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Rebif® (interferon beta-1a) is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if Rebif is safe and effective in children.